Vima Therapeutics is expanding to Parkinson’s disease following early clinical results showed proof of concept for its drug in isolated dystonia, a rare neurological movement disorder. The startup says its drug could address the biology underpinning many movement disorders.
The post Startup Vima Adds Parkinson’s to Movement Disorder Scope, Expanding Series A Round to $100M appeared first on MedCity News.
